Eisai appoints Ivor Macleod SVP, chief financial officer and chief compliance officer

2 June 2015

Japanese drug major Eisai (TYO: 4523) has appointed Ivor Macleod as senior vice president, chief financial officer and chief compliance officer of its US pharma subsidiary.

Mr Macleod will lead Eisai’s financial operations in the Americas, and head the compliance and internal audit functions.

He brings more than three decades of financial and operational expertise, including leading the financial teams at several major pharma companies in the USA and Europe. Most recently he was vice president of finance for the global research and development division of Merck & Co (NYSE: MRK).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK